Research & Development

Investigational Therapeutic for Episodic Cardiovascular Conditions

We are studying our lead investigational candidate etripamil for the acute treatment of patients with PSVT and other episodic cardiovascular conditions, including atrial fibrillation and angina, wherever they occur.

Clinical trials are a critical part of the drug development process designed to assess an investigational agent’s safety and effectiveness in treating a disease, adding to the industry knowledge on diseases and how they may be treated.

For information regarding access to Milestone’s clinical trials, please visit clinicaltrials.gov.


Current and Future Clinical Trials

We are actively recruiting patients for our Phase 3 clinical program.

See a description of our Node-301 Phase 3 clinical trial on clinical.trials.gov.

See a description of our Node-302 Phase 3 clinical trial clinical.trials.gov.

See a description of our Node-303 Phase 3 clinical trial clinical.trials.gov.

We continue to plan other clinical trials testing etripamil for the acute treatment of PSVT. We are also planning to initiate Phase 2 clinical trials in atrial fibrillation and angina to establish proof-of-concept for the broader use of etripamil in episodic cardiovascular conditions.